The Food and Drug Administration (FDA) has approved Xtoro (finafloxacin otic suspension; Alcon) for the treatment of acute otitis externa (also known as swimmer's ear) caused by Pseudomonas aeruginosa and Staphylococcus aureus.
Some people with cochlear implants experience pain, discomfort, and problems with the implant's internal magnet when they undergo magnetic resonance imaging (MRI).
Nearly one million patient visits are made to doctors offices, outpatient clinics, and emergency departments for keratitis each year in the United States, with contact lens wear as the single largest risk factor for microbial keratitis.
Featured courses from mycme
This module reviews all topics on the NCCPA examination blueprint relating to Pulmonology, Ophthalmology, and ...
This activity covers the diagnosis and management of acute otitis externa and proposes a grading ...
An understanding of the growing problem of allergic disease, how AD is the entryway into ...
- Long-Term Effects of Antivirals in Patients with HBV-Related Cirrhosis
- For Idiopathic Pericarditis, Is Standard Therapy Still the Best?
- How Effective Is Drug Therapy in Treating Anxiety and Comorbid Alcohol Use Disorders?
- Remission in Crohn's: Most Effective Tx ID'ed in Meta-Analysis
- Many Seniors Not Reporting Falls to Physician